Shipping of therapeutic somatic cell products
نویسندگان
چکیده
منابع مشابه
The Therapeutic Effects of Bioactive Compounds in Honeybee Products
Honey, royal jelly, propolis, and bee pollen are potentially beneficial to humans due to their bioactive agents. Different molecules of these honeybee products have been extracted and pharmacologically characterized. Phenolic acid, Major Royal Jelly Proteins (MRJPs), and oligosaccharides are major bioactive substances of these products. Propolis, especially Brazilian type, contains caffeic acid...
متن کاملCell-based therapeutic products: potency assay development and application.
Potency is a critical quality attribute of biological products, defined by the US FDA as the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result. Ideally, a potency assay will leverage the product's mechanism of actio...
متن کاملToxin-antitoxin selection for isolating somatic cell fusion products between any cell types.
A selective system was developed that permits the isolation of heterokaryons and cell hybrids between any cell types without the use of selectable genetic markers. Antibodies were introduced into two populations of non-transformed normal diploid human fibroblasts by the osmotic lysis of pinosomes containing hypertonic antibody solutions. Heterokaryons formed by fusing antiricin-injected cells t...
متن کاملTherapeutic equivalence of mesalamine products.
No bioequivalence studies have been conducted for mesalamine because of differences in formulation. Based on U.S. Food and Drug Administration definitions for bioequivalence, none of these drugs can be classified as bioequivalent or therapeutically equivalent. No adequate comparative trials have been conducted with equivalent mesalamine doses to determine if any of the current formulations are ...
متن کاملAfter introduction of advanced therapeutic medicinal products (ATMPs) in Ischemic Stroke; novel therapeutic modalities from financial perspective
Stroke, is accounting for more than 34% of total healthcare spending globally. Ischemic stroke (IS) accounts for 62.4% of incident stroke cases. IS-related direct medical expenditures place a considerable burden on healthcare system. The burden is more prominent in developing countries where limitations in insurance coverage is a big concern. It would be less challenging in developed countries,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cytotherapy
سال: 2011
ISSN: 1465-3249
DOI: 10.3109/14653249.2010.506507